2018
Authors: Tierrablanca LE, Ochalek J, Ford D, et al; for BREATHER (PENTA 16) Trial Group
Published in: Medicine (Baltimore). 2018;97(5):e9698
Objectives To analyze the cost effectiveness of short-cycle therapy (SCT), where patients take antiretroviral (ARV) drugs 5 consecutive days a week and have 2 days off, as an alternative to continuous ARV therapy for young people infected with human immunodeficiency virus (HIV) and taking efavirenz-based first-line ARV drugs.
2018
Authors: Turkova A, Moore CL, Butler K, et al. for BREATHER (PENTA 16) Trial Group.
Published in: PLos One. 2018;13(4):e0196239.
Background Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks.
2017
Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T.
Published in: BMJ Open. 2017;7(2):e012934
Objectives A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off) with continuous efavirenz (EFV)-based antiretroviral therapy (CT) in children and young people (aged 8–24) living with HIV with viral load <50 c/mL to examine adaptation,
2017
Authors: Namukwaya S, Paparini S, Seeley J, Bernays S.
Published in: Front Public Health. 2017;5:343.
Abstract: Despite great advances in pediatric HIV care, rates and the extent of full disclosure of HIV status to infected children remain low especially in resource-constrained setting. The World Health Organisation recommends that, by the age of 10-12 years old,
2017
Authors: Bernays S, Paparini S, Seeley J, Rhodes T.
Published in: Med Anthropol. 2017;36(5):485-499.
Abstract: Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people’s perspectives on the complex host of social and relational challenges they face in dealing with their treatment in secret and their condition in silence.
2016
Author: Butler K, Inshaw J, Ford D, et al.
Published in: Health Technol Assess. 2016;20(49):1-108.
Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings.
Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy;
2016
Author: The BREATHER (PENTA 16) Trial Group
Published in: Lancet HIV. 2016;3(9):e421-430
Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).
2016
Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley
Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68
Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event,
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T
Published: BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148)
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams.
Published in: accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
2015
Authors: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Karina M. Butler on behalf of the BREATHER trial team
Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015.
Abstract For HIV-1 infected young people (YP) facing lifelong ART, short cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity and better adherence, as well as cost savings.
2015
Authors: Harrison L, Melvin A, Fiscus S, et al; PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: J Acquir Immune Defic Syndr. 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.